Reaction

Skin Tightness reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,628 reports · 83 co-occurring drugs

As of the last recalculation, Skin Tightness appears in 4,628 FAERS reports alongside 83 co-occurring drug terms. The strongest observed disproportionality signal is EPOETIN ALFA (PRR 60.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Epoetin Alfa	154	60.4	61.2
Adapalene	903	27.5	27.6
Sulfur	50	27.0	27.1
Iron Sucrose	49	23.4	23.5
Salicylic Acid	239	21.4	21.5
Onabotulinumtoxina	298	18.5	18.6
Paricalcitol	55	17.7	17.8
Botulinum Toxin Type A	30	10.9	11.0
Erythropoietin	47	10.4	10.4
Tretinoin	18	10.0	10.0
Quinine	19	10.0	10.0
Calcitriol Capsules 0.25 Mcg	37	8.4	8.4
Calcitriol Capsules 0.5 Mcg	37	8.4	8.4
Calcitriol	37	8.3	8.3
Nitrofurantoin	22	6.0	6.0
Nitrofurantoin (Monohydrate/Macrocrystals)	22	5.9	6.0
Cinacalcet Hydrochloride	58	5.7	5.7
Brimonidine Tartrate	22	5.6	5.6
Meperidine Hydrochloride	11	5.4	5.4
Isosorbide Dinitrate	23	5.3	5.3
Enalapril Maleate	29	5.3	5.3
Nifedipine	53	5.1	5.1
Iohexol	9	4.9	4.9
Clonidine	55	4.9	4.9
Clobetasol Propionate Ointment Usp, 0.05%	11	4.8	4.8
Clobetasol Propionate	11	4.8	4.8
Sevelamer Carbonate	12	4.7	4.7
Captopril	10	4.7	4.7
Mometasone	19	4.7	4.7
Darbepoetin Alfa	55	4.6	4.6
Antacid	46	4.4	4.4
Felodipine Extended-Release Tablets	11	4.4	4.4
Felodipine	11	4.4	4.4
Extended Phenytoin Sodium	16	4.3	4.3
Diltiazem Hydrochloride	32	4.2	4.2
Asfotase Alfa	9	4.0	4.0
Nemolizumab-Ilto	11	3.9	3.9
Sodium Bicarbonate	20	3.9	3.9
Sodium Bicarbonate Injection,	20	3.9	3.9
Dapsone	9	3.8	3.8
Panitumumab	13	3.7	3.7
Daspone	8	3.7	3.7
Dapsone Gel, 5%	8	3.7	3.7
Amlodipine Besylate	118	3.7	3.7
Metoroprolol Tartrate	53	3.6	3.6
Hydroxyzine	38	3.6	3.6
Minoxidil	35	3.5	3.5
Minoxidil Foam 5% (Womens)	25	3.4	3.4
Valganciclovir	14	3.3	3.3
Valganciclovir Hydrochloride	14	3.3	3.3
Colchicine	19	3.3	3.3
Multivitamin	36	3.3	3.3
Doxazosin Mesylate	25	3.1	3.1
Chlorthalidone	8	3.1	3.1
Doxazosin	19	3.1	3.1
Biotin	21	3.0	3.0
Crisaborole	6	2.8	2.8
Losartan Potassium	48	2.8	2.8
Alpelisib	5	2.6	2.6
Alteplase	8	2.4	2.4
Bimatoprost	15	2.3	2.3
Lapatinib	8	2.3	2.3
Amphetamine	4	2.2	2.2
Dupilumab	220	2.1	2.1
Macitentan	30	2.0	2.0
Ticagrelor	13	1.8	1.8
Encorafenib	4	1.8	1.8
Naproxen Sodium Tablet	20	1.7	1.7
Ruxolitinib	27	1.7	1.7
Buprenorphine Hydrochloride, Naloxone Hydrochloride	9	1.7	1.7
Pegvaliase-Pqpz	3	1.6	1.6
Alirocumab	9	1.6	1.6
Orlistat	9	1.6	1.6
Diroximel Fumarate	4	1.5	1.5
Avapritinib	4	1.5	1.5
Treprostinil	41	1.5	1.5
Crizotinib	4	1.4	1.4
Dimethyl Fumarate	38	1.4	1.4
Ixekizumab	10	1.2	1.2
Glatiramer Acetate	16	1.2	1.2
Relugolix	6	1.1	1.1
Guselkumab	6	0.8	0.8
Pimavanserin Tartrate	6	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.